PVLA

Palvella Therapeutics
PVLA

Overview Fund Trends Analyst Outlook Journalist View
76.22 USD
+6.32
9.04%
At close Updated Oct 13, 4:00 PM EDT
Pre-market
After hours
74.75
--1.47
1.93%
1 day
9.04%
5 days
11.12%
1 month
39.52%
3 months
176.66%
6 months
211.87%
Year to date
535.17%
1 year
368.47%
5 years
-59.63%
10 years
-49.05%
 

About: Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.

Employees: 14

Healthcare Biotechnology
0
Funds holding %
of 7,491 funds
Explore Fund Trends
0
Analysts bullish %
of 8 analysts
See Analyst Ratings
0
Positive news %
of 6 articles
Check Journalist View
Price charts implemented using Lightweight Charts™